5 Topic Commentaries

Musings from The Power List: Miguel Forte

• 

  Louis J. Picker, MD

  Immunology, Vaccinology

  •

  Oregon Health & Science University, Vaccine and Gene Therapy Institute

  The people who jumped on this right away are the people who had vaccine platforms that were conducive for this that were simply sitting there. All they had to do is basically figure out what part of [the virus] they were going to put in the vaccine and then run with it.

  Source
• 

  Drew Weissman, MD, PhD

  mRNA vaccines, Immunology

  •

  Perelman School of Medicine, University of Pennsylvania

  We were making RNA within a week or so

  Source
• 

  Francis S. Collins, MD, PhD

  Medical genetics; Biomedical research leadership

  •

  National Institutes of Health

  at a remarkably rapid pace compared to the usual pace for vaccine preparation,

  Source
• 

  Peter Marks, MD, PhD

  Regulatory science (biologics); Hematology/Oncology

  •

  U.S. Food and Drug Administration

  Severe hypoglycemia is a dangerous condition that can lead to injuries resulting from loss of consciousness or seizures. Today’s approval, the first-ever cell therapy to treat patients with type 1 diabetes, provides individuals living with type 1 diabetes and recurrent severe hypoglycemia an additional treatment option to help achieve target blood glucose levels.

  Source
• 

  Nicole Verdun, MD

  Regulatory science (cell and gene therapy)

  •

  U.S. Food and Drug Administration

  MLD is a devastating disease that profoundly affects the quality of life of patients and their families. Advancements in treatment options offer hope for improved outcomes and the potential to positively influence the trajectory of disease progression. This approval represents important progress in the advancement and availability of effective treatments, including gene therapies, for rare diseases.

  Source